VEGF-A in serum protects against memory impairment in APP/PS1 transgenic mice by blocking neutrophil infiltration

Mol Psychiatry. 2023 Oct;28(10):4374-4389. doi: 10.1038/s41380-023-02097-w. Epub 2023 Jun 6.

Abstract

Activation of innate immunity in the brain is a prominent feature of Alzheimer's disease (AD). The present study investigated the regulation of innate immunity by wild-type serum injection in a transgenic AD mouse model. We found that treatment with wild-type mouse serum significantly reduced the number of neutrophils and microglial reactivity in the brains of APP/PS1 mice. Mimicking this effect, neutrophil depletion via Ly6G neutralizing antibodies resulted in improvements in AD brain functions. Serum proteomic analysis identified vascular endothelial growth factor-A (VEGF-A) and chemokine (C-X-C motif) ligand 1 (CXCL1) as factors enriched in serum samples, which are crucial for neutrophil migration and chemotaxis, leukocyte migration, and cell chemotaxis. Exogenous VEGF-A reversed amyloid β (Aβ)-induced decreases in cyclin-dependent kinase 5 (Cdk5) and increases in CXCL1 in vitro and blocked neutrophil infiltration into the AD brain. Endothelial Cdk5 overexpression conferred an inhibitory effect on CXCL1 and neutrophil infiltration, thereby restoring memory abilities in APP/PS1 mice. Our findings uncover a previously unknown link between blood-derived VEGF signaling and neutrophil infiltration and support targeting endothelial Cdk5 signaling as a potential therapeutic strategy for AD.

MeSH terms

  • Alzheimer Disease* / therapy
  • Amyloid beta-Peptides*
  • Amyloid beta-Protein Precursor / genetics
  • Animals
  • Disease Models, Animal
  • Memory Disorders
  • Mice
  • Mice, Transgenic
  • Neutrophil Infiltration
  • Presenilin-1 / genetics
  • Proteomics
  • Vascular Endothelial Growth Factor A

Substances

  • Amyloid beta-Peptides
  • Vascular Endothelial Growth Factor A
  • Amyloid beta-Protein Precursor
  • Presenilin-1